Oral treprostinil for the treatment of pulmonary arterial hypertension in patients transitioned from parenteral or inhaled prostacyclins: case series and treatment protocol

Por Coons, James C., Miller, Taylor, Simon, Marc A., Ishizawar, David C., Mathier, Michael A.
Publicado no Pulm Circ (2016)

Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension

Por Rajkumar, Revathi, Konishi, Kazuhisa, Richards, Thomas J., Ishizawar, David C., Wiechert, Andrew C., Kaminski, Naftali, Ahmad, Ferhaan
Publicado em 2010

Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension

Por Preston, Ioana R., Feldman, Jeremy, White, James, Franco, Veronica, Ishizawar, David, Burger, Charles, Waxman, Aaron B., Hill, Nicholas S.
Publicado no Pulm Circ (2014)

The ß1‐Adrenergic Receptor Mediates the Pharmacogenetic Interaction of the ACE D Allele and ß‐Blockers

Por Ishizawar, David C., Janosko, Karen M., Teuteberg, Jeffrey J., Cadaret, Linda M., Mathier, Michael A., McNamara, Dennis M.
Publicado no Clin Transl Sci (2008)

High Mobility Group Box 1 Contributes to the Pathogenesis of Experimental Pulmonary Hypertension via Activation of Toll-like Receptor 4

Por Bauer, Eileen M, Shapiro, Richard, Zheng, Han, Ahmad, Ferhaan, Ishizawar, David, Comhair, Suzy A, Erzurum, Serpil C, Billiar, Timothy R, Bauer, Philip M
Publicado em 2012